Incorporating ADCs into the treatment of mBC: Practical considerations for the community oncologist

touchIN CONVERSATION for touchONCOLOGY Listen to two oncologists discuss the incorporation of antibody–drug conjugates (ADCs) into the treatment of metastatic breast cancer, tackling questions submitted by the oncology community. They discuss how treatment can be guided by biomarkers, give practical insights into creating a personalized care plan for patients, and share strategies for managing ADC-associated toxicities. The experts Prof. Giuseppe Curigliano, European Institute of Oncology and University of Milan, Italy Dr Alison Conlin, Providence Cancer Institute, Portland, OR, USA This touchPODCAST is for HCPs outside of the UK.  This activity is funded by an independent medical education grant from Gilead Sciences, Inc. The activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information, visit our website: https://touchoncologyime.org/adcs-in-the-treatment-of-mbc/